GlassScriptPhysician profile
Rosa A Tang
NPI 1891797460
$136,644.38
in general payments reported to CMS, 2019-2025
29 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $7,886 · 2021: $7,715 · 2022: $3,245 · 2023: $39K · 2024: $4,282 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $7,573 · Food and Beverage: $4,319 · Consulting Fee: $3,840 · Honoraria: $1,470 · Debt Forgiveness: $66.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,940.00 |
| Travel and Lodging | $7,573.37 |
| Food and Beverage | $4,319.28 |
| Consulting Fee | $3,840.00 |
| Honoraria | $1,470.00 |
| Debt Forgiveness | $66.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $105,881.71 | 2019-2024 | Mavenclad |
| Horizon Therapeutics Plc | $19,758.82 | 2019-2023 | Tepezza, Uplizna |
| Amgen INC. | $3,996.10 | 2024-2025 | Tepezza, Uplizna |
| Alexion Pharmaceuticals, INC. | $2,916.56 | 2019-2025 | Soliris, Ultomiris |
| Argenx US, INC. | $900.00 | 2023 | Vyvgart |
| Harrow Eye, LLC | $807.09 | 2024-2025 | Vevye |
| Genzyme Corporation | $603.73 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $414.32 | 2019-2023 | |
| Genentech USA, INC. | $223.22 | 2019-2024 | Ocrevus, Enspryng |
| Teva Pharmaceuticals USA, INC. | $160.26 | 2019-2020 | |
| Dompe US, INC. | $148.22 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $118.80 | 2024-2025 | Acthar |
| Ablative Solutions, INC. | $114.51 | 2019 | |
| Akcea Therapeutics, INC. | $111.79 | 2020 | |
| Penumbra, INC. | $74.22 | 2024 | Penumbra Coil 400 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $69.99 | 2019 | |
| Optos, INC. | $66.05 | 2023 | Panoramic Ophthalmoscope |
| Bausch & Lomb Americas INC. | $56.63 | 2024-2025 | Xiidra, Miebo |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Shire North American Group INC | $37.58 | 2019 | |
| Oyster Point Pharma, INC. | $23.76 | 2023 | Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $21.98 | 2021 | |
| Neurocrine Biosciences, INC. | $20.72 | 2019 | |
| Thea Pharma INC. | $19.82 | 2023 | |
| Maculogix, INC. | $17.58 | 2019 | |
| Sight Sciences, INC. | $16.69 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.84 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.59 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.